Compare Amphastar Pharmaceuticals Inc (AMPH) vs FirstEnergy Corp. (FE) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

FirstEnergy (FE) trades at $47.92, up 0.61% with neutral technical signals. The company shows steady revenue growth to $15.09B in 2025 and a net income margin of 6.86%, though cash flow remains negative. Recent news highlights opportunities from surging data center demand and a $36B investment plan for grid upgrades. Analyst consensus is mixed with a $52 price target, indicating potential upside from current levels.

Outlook is cautiously optimistic given FE's strategic investments and data center tailwinds, but risks include regulatory uncertainty and high debt levels. The stock presents a balanced opportunity for investors seeking utility exposure with growth potential, though monitoring earnings execution and capex efficiency is crucial for sustained performance.